Finding: Treatment of b-cell lymphomas refractory to pd1-blockade with both oki-179 and anti-pd1 inhibited growth; furthermore, sensitivity to single or combined treatment required tumor-derived mhc class i, and positively correlated with mhc class ii expression level.
Certainty (1-5): 5